Back to Report Store Home

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

  • Published: May-2018
  • Report Code: GBIHC475MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 A Complex and Poorly Understood Disorder with Numerous Unmet Needs 5

2.2 Development and Influence of Antipsychotics 5

2.3 Small Pipeline for Schizophrenia with Few Signs of Innovation 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Product Developments Remain Attractive 7

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 8

3.5 Sustained Innovation in Schizophrenia 8

4 Clinical and Commercial Landscape 10

4.1 Overview of Schizophrenia 10

4.2 Symptoms 10

4.3 Diagnosis 11

4.4 Disease Etiology 12

4.5 Disease Pathophysiology 12

4.5.1 Susceptibility Genes 13

4.5.2 Neurotransmission Alterations 14

4.5.3 Phosphatidylinositol Signaling 16

4.6 Epidemiology 16

4.7 Co-morbidities and Complications 16

4.7.1 Anxiety 16

4.7.2 Depression 16

4.7.3 Post-Traumatic Stress Disorder 17

4.7.4 Obsessive Compulsive Disorder 17

4.7.5 Panic Disorder 17

4.7.6 Cognitive Impairment 17

4.8 Prognosis 17

4.9 Treatment 17

4.10 Overview of Marketed Products 18

4.10.1 Molecule Type and Target Analysis 18

4.11 Current Unmet Needs 19

5 Assessment of Pipeline Product Innovation 20

5.1 Overview 20

5.2 Pipeline by Stage of Development and Molecule Type 20

5.3 Pipeline by Molecular Target 21

5.4 Comparative Distribution of Programs between Schizophrenia Disease Market and Pipeline by Therapeutic Target Family 22

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 23

5.6 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 25

5.7 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 25

5.8 List of All First-in-Class Pipeline Programs 26

6 Schizophrenia Pathophysiology and Innovation Alignment 31

6.1 Complexity of Signaling Networks in the Schizophrenia 31

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 32

6.3 First-in-Class Molecular Target Matrix Assessment 32

7 First-in-Class Molecular Target Evaluation 34

7.1 Pipeline Programs Targeting XXX 34

7.2 Pipeline Programs Targeting XXX 35

7.3 Pipeline Programs Targeting XXX 37

7.4 Pipeline Programs Targeting XXX 38

7.5 Pipeline Programs Targeting XXX 40

7.6 Pipeline Programs Targeting XXX 41

8 Deals and Strategic Consolidations 44

8.1 Industry-Wide First-in-Class Deals 44

8.2 Licensing Deals 45

8.2.1 Deals by Region, Value and Year 45

8.2.2 Deals by Stage of Development and Value 46

8.2.3 Deals by Molecule Type and Molecular Target 47

8.2.4 List of Deals with Disclosed Deal Values 48

8.3 Co-development Deals 49

8.3.1 Deals by Region, Value and Year 49

8.3.2 Deals by Stage of Development and Value 50

8.3.3 Deals by Molecule Type and Molecular Target 51

8.3.4 List of Deals with Disclosed Deal Values 52

8.4 First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals 52

9 Appendix 54

9.1 References 54

9.2 Abbreviations 61

9.3 Methodology 62

9.3.1 Data Integrity 62

9.3.2 Innovative and Meaningful Analytical Techniques and Frameworks 62

9.3.3 Evidence Based Analysis and Insight 62

9.4 Secondary Research 62

9.4.1 Market Analysis 62

9.4.2 Pipeline Analysis 62

9.4.3 Licensing and Co-development Deals 63

9.5 Contact Us 63

9.6 Disclaimer 64

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards